As of May 28, 2025, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) reports a ROE (Return on Equity) of 0.87%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity)
Over recent years, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 0.87% |
| 2023-12-31 | 9.82% |
| 2022-12-31 | 38.37% |
| 2021-12-31 | 45.26% |
| 2020-12-31 | 26.51% |
This slight downward trend highlights how Beijing Wantai Biological Pharmacy Enterprise Co Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity) to Peers
To better understand Beijing Wantai Biological Pharmacy Enterprise Co Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) | 0.87% |
| Xiamen Amoytop Biotech Co Ltd (688278.SS) | 32.41% |
| Shanghai Henlius Biotech Inc (2696.HK) | 27.23% |
| Imeik Technology Development Co Ltd (300896.SZ) | 25.11% |
| Shenzhen New Industries Biomedical Engineering Co Ltd (300832.SZ) | 21.32% |
| Anhui Anke Biotechnology Group Co Ltd (300009.SZ) | 17.14% |
Compared to its competitors, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.